Full Press Release Details
Oncolytics Biotech Inc. Announces
Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN in Combination with Bortezomib
CALGARY, Nov. 18, 2015 /CNW/ - Oncolytics
Biotech Inc. ("Oncolytics") (TSX:ONC, OTCQX:ONCYF) today announced that enrollment has commenced in a Phase Ib study
of REOLYSIN combined with standard doses of bortezomib (Kyprolis ) and dexamethasone in patients
with relapsed or refractory multiple myeloma (REO 019). Kevin Kelly, M.D., Ph.D. of the Keck School of Medicine of the University
of Southern California (USC), is the principal investigator.
"We recently announced
promising early results from another multiple myeloma study examining REOLYSIN in combination with carfilzomib,"
said Dr. Brad Thompson, President and CEO of Oncolytics. "Our goal is to determine how REOLYSIN performs with
the standard of care options in this difficult to treat indication and then take the best combination forward into later-stage
The study is a two-stage
open-label Phase Ib trial of adult patients with relapsed or refractory multiple myeloma following at least one line of therapy.
The study objectives include determining the maximum tolerated dose ("MTD") and the safety profile of REOLYSIN
in combination with bortezomib and dexamethasone, as well as exploring the toxicities and the pharmacodynamics of the treatment
combination, and determining the preliminary response rate in patients with relapsed or refractory multiple myeloma.
Adult patients will receive
REOLYSIN on days 1, 2, 8, 9, 15 and 16 of each 28-day cycle. Patients will also receive bortezomib and dexamethasone
on days 1, 8 and 15.The first stage of the study will enroll three to six patients in each of two cohorts, with each cohort at
a different dose level. The second stage of the study will enroll up to 12 patients at the MTD reached in the first stage.
About Multiple Myeloma
Multiple Myeloma is a cancer of the plasma cells and the second most common hematological malignancy. The American Cancer Society
estimates there will be 26,850 new cases diagnosed in the United States and 11,240 deaths from the disease in 2015.
About Oncolytics Biotech
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange
Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than
statements of historical facts, included in this press release that address activities, events or developments that Oncolytics
expects or anticipates will or may occur in the future, including such things as, the Company's expectations related to the phase
1b study in relapsed or refractory multiple myeloma, future trials in this indication, the Company's belief as to the potential
of REOLYSIN as a cancer therapeutic, and other such matters are forward-looking statements and forward-looking
information and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially
from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others,
risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds
and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the
tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials,
the Company's ability to successfully commercialize REOLYSIN , uncertainties related to the research and development
of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual
filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the
forward-looking statements and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking
statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking
information, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: NATIONAL Equicom, Nick Hurst, 800
6th Ave. SW, Suite 1600, Calgary, Alberta T2P 3G3, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@national.ca; NATIONAL Equicom,
Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@national.ca; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd
Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 18-NOV-15